Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
84611-23-4
Molecular formula
C8H11NO4S2
Molecular weight
249.299 g/mol
Drug class
Mucolyticprodrug with thiol-containing active metabolite
Mechanism of action
Erdosteine is a prodrug. First-pass metabolism releases free thiol groups that open disulphide bonds in bronchial mucoproteins, reducing mucus viscosity. The active metabolite also has antioxidant activity and can inhibit bacterial adhesion to epithelial cells.
Indications / reported uses
Expectorant and symptomatic treatment of acute exacerbations of chronic bronchitis in adults under the cited UK SmPC; other national product information may include additional acute/chronic respiratory conditions with excessive mucus
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Erdosteine Environmental Risk Assessment (ERA) (the Erdosteine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.